Here in the US, Genentech, known for their cancer drugs and research is expected to be hit as well, although no particular numbers are out. Last year Roche took over Genentech for $47 billion, huge purchase here, but the company always had maintained...
Filed under: Medically Related, Pharma/FDA News, Pharma, Biotech, Cancer, Oncology, Marketing, Genentech, Roche, Research and Development, Sales, Layoffs, RNAi